COMPANY
Merlin Therapeutics
NIH awards 3
- NIH award 5R44NS145814-02 FY2026: $1,500,000 awarded for that fiscal year; activity R44 (SBIR); PI YANG, NA NORA; recipient as written: MERLIN THERAPEUTICS INC, KING OF PRUSSIA, PA. AAV-mediated delivery of the infla source ↗
- NIH award 1R44NS145814-01 FY2025: $1,256,291 awarded for that fiscal year; activity R44 (SBIR); PI YANG, NA NORA; recipient as written: MERLIN THERAPEUTICS INC, KING OF PRUSSIA, PA. AAV-mediated delivery of the infla source ↗
- NIH award 1R41NS135883-01 FY2024: $699,559 awarded for that fiscal year; activity R41 (STTR); PI HENWOOD, NICOLE; recipient as written: MERLIN THERAPEUTICS INC, KING OF PRUSSIA, PA. Development of a Novel AAV9 Gene R source ↗
Funding and NIH signals
- NIH award NIH awarded $1.5M (SBIR Phase II 5R44NS145814-02, continuation, notice Aug 14, 2026). NIH RePORTER 5R44NS145814-02 (Aug 14, 2026)
Evidence (1 event)
- Aug 14, 2026 · NIH RePORTER 5R44NS145814-02
Organization: MERLIN THERAPEUTICS INC; City/State: KING OF PRUSSIA, PA; Project number: 5R44NS145814-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 1500000; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: AAV-mediated delivery of the inflammasome adapter protein, ASC, as a pro-apoptotic gene therapy for schwannoma; Organization type: Domestic For-Profits
- Aug 14, 2026 · NIH RePORTER 5R44NS145814-02